baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

UC WAR. CALL 06/24 AXI/ DE000HC9VPM8 /

11/06/2024 13:47:08	Chg.0.0000	Bid11/06/2024	Ask-	Underlying	Strike price	Expiration date	Option type
0.0010EUR	0.00%	0.0010 Bid Size: 80,000	- Ask Size: -	Atos SE	6.00 -	19/06/2024	Call

GlobeNewswire 05/06 Atossa to Present at the Sidoti Small-Cap Investor Conference

GlobeNewswire 30/05 Groundbreaking Technology Solves Major Problem of User Lockouts During MFA Resets

GlobeNewswire 28/05 NetLogistik Wins Partner Leadership Award from Blue Yonder

GlobeNewswire 28/05 Atossa Therapeutics Announces Support of Clinical Study Testing New, Artificial Intelligence, Breast...

GlobeNewswire 16/05 Nametag Enlisted by Newfold Digital in the Fight Against Fraud and Cybersecurity Threats

GlobeNewswire 15/05 Atossa Therapeutics Announces Last Patient, Last Dose in its Phase 2 Karisma-Endoxifen Clinical Tria...

GlobeNewswire 15/05 Calian Reports Record Results for the Second Quarter

GlobeNewswire 13/05 Atossa Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update

GlobeNewswire 13/05 NVIDIA Grace Hopper Ignites New Era of AI Supercomputing

GlobeNewswire 07/05 Atossa Therapeutics Announces Support of New Breast Cancer Screening Guidelines

GlobeNewswire 29/04 Atossa Therapeutics Announces Expanded Research Agreement with Weill Cornell Medicine to Further Eva...

GlobeNewswire 15/04 Atossa Therapeutics and Quantum Leap Healthcare Announce I-SPY 2 Clinical Trial to Evaluate (Z)-Endo...

GlobeNewswire 11/04 Atossa to Participate in Noble Capital Markets Emerging Growth Healthcare Conference

GlobeNewswire 09/04 Atossa Therapeutics Presents Data from 40mg Cohort of Phase 2 EVANGELINE Clinical Trial Showing 100%...

GlobeNewswire 01/04 Atossa Therapeutics Announces Year-End 2023 Financial Results and Provides Corporate Update

GlobeNewswire 27/03 Calian Announces the Appointment of New President of Advanced Technologies

GlobeNewswire 25/03 Nametag Launches Self-Service Account Recovery Solution That Stops AI-Generated Deepfake Attacks

GlobeNewswire 19/03 Atossa Therapeutics Provides Five-Year (Z)-Endoxifen Treatment Update on FDA-Approved "Expanded Acce...

GlobeNewswire 18/03 Atossa Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Listing Requirements

GlobeNewswire 12/03 Atossa Therapeutics Appoints Breast Cancer Specialist Tessa Cigler, M.D., M.P.H. to its Board of Dir...

GlobeNewswire 06/03 Data from Atossa’s Phase 2 EVANGELINE Clinical Trial to be Presented at American Association for Can...

GlobeNewswire 22/02 Atossa Therapeutics Announces First Patient Dosing of (Z)-Endoxifen in the Ongoing RECAST DCIS Study

GlobeNewswire 16/01 New report reveals that 94% of global organizations have experienced email security incidents last y...

GlobeNewswire 09/01 Atossa Therapeutics Issues Letter to Shareholders

TeleTrader 03/01 Europe opens mixed with data, business in focus

UC WAR. CALL 06/24 AXI/ DE000HC9VPM8 /

If you wish to receive reply to your feedback, please provide your email address.